Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs

Diabetes Research and Clinical Practice

Volumn 96, Issue 3, 2012, Pages

  Dungan, Kathleen M ^a   Buse, John B ^b   Herman, William H ^c   Arakaki, Richard F ^d   Jiang, Honghua H ^e   Jacobson, Jennie G ^e   Fahrbach, Jessie L ^e  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

1,5 Anhydroglucitol; Glargine; Insulin lispro mix 25

Indexed keywords

1,5 ANHYDROSORBITOL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

BLOOD GLUCOSE; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84862232812     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.02.005     Document Type: Article

References (15)

1. Pogach L., Engelgau M., Aron D. Measuring progress toward achieving hemoglobin A1c goals in diabetes care: pass/fail or partial credit. JAMA 2007, 297:520-523.
2. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
3. Rodbard H.W., Jellinger P.S., Davidson J.A., Einhorn D., Garber A.J., Grunberger G., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
4. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
5. Davidson J. Strategies for improving glycemic control: effective use of glucose monitoring. Am J Med 2005, 118(Suppl 9A):27S-32S.
6. Yamanouchi T., Tachibana Y., Akanuma H., Minoda S., Shinohara T., Moromizato H., et al. Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am J Physiol 1992, 263:E268-E273.
7. Yamanouchi T., Minoda S., Yabuuchi M., Akanuma Y., Akanuma H., Miyashita H., et al. Plasma 1,5-anhydro-d-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 1989, 38:723-729.
8. Yamanouchi T., Moromizato H., Shinohara T., Minoda S., Miyashita H., Akaoka I Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol. Metabolism 1992, 41:862-867.
9. Yamanouchi T., Ogata N., Tagaya T., Kawasaki T., Sekino N., Funato H., et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 1996, 347:1514-1518.
10. Dungan K.M., Buse J.B., Largay J., Kelly M.M., Button E.A., Kato S., et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006, 29:1214-1219.
11. Dungan K., Fahrbach J., Jiang H., Martin S.A. Relationship of 1,5-anhydroglucitol (1,5-AG) to other baseline characteristics in insulin-naïve type 2 diabetes (T2D) patients in the DURABLE trial. American Diabetes Association 68th annual scientific sessions 2008, Abstract #984.
12. McGill J.B., Cole T.G., Nowatzke W., Houghton S., Ammirati E.B., Gautille T., et al. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 2004, 27:1859-1865.
13. Monnier L., Colette C., Dunseath G.J., Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007, 30:263-269.
14. Fahrbach J., Jacober S., Jiang H., Martin S. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. J Diabetes Sci Technol 2008, 2:831-838.
15. Buse J.B., Wolffenbuttel B.H., Herman W.H., Shemonsky N.K., Jiang H.H., Fahrbach J.L., et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009, 32:1007-1013.